NCT05830760

Expression of Sodium-glucose Co-transporter 2 in Human Heart

Name: Clinical Trial NCT05830760
Creator: University Hospital, Strasbourg, France
Keywords: Aortic Valve Stenosis, Myocardium biopsy, biological, clinical trial, France

Expression of Sodium Glucose Co-transporter2 in Myocardium From Patients With Aortic Valve Stenosis and With/Without Diastolic Heart Failure

University Hospital, Strasbourg, France·ClinicalTrials.gov·biologicalNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Aortic Valve Stenosis
Drug/Device/Intervention: Myocardium biopsy
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: University Hospital, Strasbourg, France
Location: Strasbourg, France

Timeline & enrollment

Phase: N/A
Start date: Jun 01, 2023
End date: Oct 01, 2025
Enrollment: 80 participants

Primary outcome

To study the expression levels of SGLT2 in the myocardium of patients with surgical aortic stenosis,To study the SGLT2 tissue localization in the myocardium of patients with surgical aortic stenosis

Summary

The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.

ICD-10 classifications

Aortic (valve) stenosisAortic (valve) stenosis with insufficiencyCongenital stenosis of aortic valveStenosis of aortaRheumatic aortic stenosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05830760
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05830760 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Strasbourg, France and is currently Not yet recruiting. The study focuses on Aortic Valve Stenosis. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.